跳至主要内容
临床试验/NCT03615807
NCT03615807已完成不适用

Randomized Study Comparing Different Durations of Antibiotic Treatment for Diabetic Foot Infections

University Hospital, Geneva1 个研究点 分布在 1 个国家目标入组 182 人开始时间: 2017年2月16日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
182
试验地点
1
主要终点
Number of Participants Experiencing Clinical Failure

研究概览

简要总结

This is a randomized, unblinded, single-centre study. After eventual surgical debridement (not amputation), patients will be randomized to receive 1 of 2 targeted antibiotic regimens, in the ratio 1:1.

For diabetic toe osteomyelitis, the patients will be randomized between a 3 and a 6 week's arm, for soft tissue infections between 10 and 20 days. The final assessments used in the primary efficacy analysis will be obtained at the test-of-cure (TOC) visit approximately 60 days after treatment is stopped.

详细描述

Diabetic foot infections (DFI) are frequent and are associated with a high burden of morbidity, costs, recurrence risk or new episodes of infections. About two-third of recurrent DFI may reveal other microorganisms than in the previous period, suggesting new episodes of infection due to the underlying problem, and/or selection by prior antimicrobial therapy. Osteomyelitis in the diabetic toe is almost always established by contiguous spread of infection from a chronic ulcer. It occurs in up to 15% of patients with a diabetic foot ulcer and about 20% of all DFI (and over half of severe infections) involve bone at presentation. The severity of a diabetic foot infection is based on the local and systemic signs and symptoms of infection and has been categorically defined in the Infectious Disease Society of America guidelines for the "Diagnosis and Treatment of Diabetic Foot Infections" (IDSA guidelines).

Knowing the potential for poor outcomes, many clinicians have tended to treat DFIs with a long duration of antibiotic therapy, with many side effects, development and spreading of antibiotic resistance, and associated costs. Data from recent comparative trials has shown that 1-2 weeks is sufficient for most soft tissue infections, and 4 to 6 weeks appears adequate in those with (unresected) infected bone. Retrospective reviews over the past two decades have demonstrated that about two-thirds of selected patients with diabetic foot osteomyelitis can achieve remission with antibiotic therapy alone (i.e., without bone resection). One recent randomized trial found that treatment with only antibiotic therapy (given for 90 days) gave similar clinical outcomes to treatment with conservative surgery (removal only of the infected bone) along with just a short course of antibiotic therapy. Another randomized trial compared a 6-week against 12-week course of antibiotic therapy, without concomitant surgery, for diabetic foot osteomyelitis and also found similar outcomes.

Likewise, the optimal antibiotic duration for any skin and soft tissue infection is unknown. According to some databases of University of Geneva Hospitals, among 378 skin and soft tissue infections in 346, overall cure was achieved in 330 episodes (87%) after a median antibiotic administration of 15 days. In multivariate Cox regression analysis, duration of antibiotic therapy (HR 1.0, 95%CI 0.96-1.02) did not influence treatment failure among patients with positive MRSA carriage.

Our study intends to optimize the duration of antibiotic therapy in DFI; for skin and soft tissue infections as well as for diabetic toe osteomyelitis that is not amputated.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 120 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diabetes mellitus
  • Diabetic Foot Infections
  • Surgical intervention to remove all necrotic tissue or tenotomy.
  • Osteomyelitis limited to bone contact or cortical lesions in X-ray.

排除标准

  • Implanted device.
  • More than 96 hours of systemic antibiotic therapy prior to inclusion
  • Destructive osteomyelitis
  • Concomitant infections requiring more than 14 days of antibiotic therapy.

研究组 & 干预措施

Short antibiotic arm

Experimental

10 days for soft tissue infections 3 weeks for osteomyelitis

干预措施: Surgical debridement (if needed) (Procedure)

Short antibiotic arm

Experimental

10 days for soft tissue infections 3 weeks for osteomyelitis

干预措施: Antibiotic duration (Drug)

Short antibiotic arm

Experimental

10 days for soft tissue infections 3 weeks for osteomyelitis

干预措施: Microbiological sampling (Diagnostic Test)

Short antibiotic arm

Experimental

10 days for soft tissue infections 3 weeks for osteomyelitis

干预措施: Revascularisation (if needed). (Procedure)

Short antibiotic arm

Experimental

10 days for soft tissue infections 3 weeks for osteomyelitis

干预措施: Off-loading (Device)

Short antibiotic arm

Experimental

10 days for soft tissue infections 3 weeks for osteomyelitis

干预措施: Patient's education and instructions (Behavioral)

Short antibiotic arm

Experimental

10 days for soft tissue infections 3 weeks for osteomyelitis

干预措施: Wound debridement (Procedure)

Standard antibiotic arm

Active Comparator

20 days for soft tissue infections 6 weeks for osteomyelitis

干预措施: Surgical debridement (if needed) (Procedure)

Standard antibiotic arm

Active Comparator

20 days for soft tissue infections 6 weeks for osteomyelitis

干预措施: Microbiological sampling (Diagnostic Test)

Standard antibiotic arm

Active Comparator

20 days for soft tissue infections 6 weeks for osteomyelitis

干预措施: Revascularisation (if needed). (Procedure)

Standard antibiotic arm

Active Comparator

20 days for soft tissue infections 6 weeks for osteomyelitis

干预措施: Off-loading (Device)

Standard antibiotic arm

Active Comparator

20 days for soft tissue infections 6 weeks for osteomyelitis

干预措施: Patient's education and instructions (Behavioral)

Standard antibiotic arm

Active Comparator

20 days for soft tissue infections 6 weeks for osteomyelitis

干预措施: Wound debridement (Procedure)

Standard antibiotic arm

Active Comparator

20 days for soft tissue infections 6 weeks for osteomyelitis

干预措施: Antibiotic duration (Drug)

结局指标

主要结局

Number of Participants Experiencing Clinical Failure

时间窗: 30-60 days

Visual and dichotomous evaluation regarding the numbers of clinical recurrence/failure

次要结局

  • Number of Participants Experiencing Adverse Events Related to the Antibiotic Therapy(30-60 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ilker Uckay

Prof. Dr. med Ilker Uçkay

University Hospital, Geneva

研究点 (1)

Loading locations...

相似试验